Publications by authors named "Fabrizio Di Costanzo"
Background: As recommended in the European Society for Medical Oncology (ESMO) guidelines, assessment of health-related quality of life (HRQoL) should be a relevant endpoint in randomized controlled trials (RCTs) testing new anticancer therapies. However, previous publications by our group and others revealed a frequent underestimation and underreporting of HRQoL results in publication of RCTs in oncology. Herein, we systematically reviewed HRQoL reporting in RCTs testing new treatments in advanced prostate, kidney and urothelial cancers and published between 2010 and 2022.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigated the relationship between quality of life (QoL) and survival outcomes (progression-free survival (PFS) and overall survival (OS)) in phase III trials of new treatments for metastatic non-small cell lung cancer (NSCLC).
- - Out of 81 reviewed randomized controlled trials, 37% showed improved QoL with experimental treatments, while QoL did not significantly differ in around 59% of trials. A significant correlation was observed between QoL and PFS, especially in studies testing targeted therapies.
- - However, QoL did not significantly correlate with OS outcomes, indicating that while some new treatments may enhance QoL, they do not always lead to longer survival rates.
Unlabelled: Breast cancer is the most frequently diagnosed cancer in women worldwide. Actually CDK4/6 inhibitor Ribociclib is approved for the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer, but comorbidities like infectious or cardiovascular diseases may limit its use.
Case Report: A 45-year-old woman was diagnosed with metastatic breast cancer in September 2021; also, her hepatitis screening resulted positive for hepatitis B infection.
Major associations of medical oncologists remark that novel anticancer treatments should guarantee improvement of survival outcomes as well as of patients' quality of life (QoL). Herein, we investigated QoL assessment and reporting in phase III randomized controlled trials (RCTs) testing new drugs in metastatic non-small cell lung cancer (NSCLC), published between 2010 and 2021. We selected 172 RCTs for further analysis.
View Article and Find Full Text PDFWe systematically reviewed QoL assessment and reporting in RCTs of immune checkpoint inhibitors (ICIs) in solid cancers published between 2013 and 2021. None of the 106 eligible trials included QoL among primary endpoints. QoL results were non-disclosed in 83/106 (78.
View Article and Find Full Text PDF